20
total announcements
TORNTPHARM.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹1.56 L Cr
P/E (TTM)
72.6
P/E (Forward)
51.3
EPS (TTM)
₹63.25
52W Low
₹2,891.45
52W High
₹4,658.75
Dividend Yield
0.79%
Beta
0.13
Price / Book
18.4
Return on Equity
26.83%
Debt / Equity
33.4
Revenue (TTM)
₹12,248 Cr
Gross Margin
75.69%
Operating Margin
26.62%
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has scheduled a teleconference with investors/analysts on 23rd October, 2026 to discuss the financial performance of the company for the quarter and half year ended 30th September, 2026.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has informed that India Ratings and Research Private Limited has affirmed the credit rating and revised the outlook from stable to positive of the Company’s existing banking facilities, issuer rating, and Non-Convertible Debentures.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 23/10/2026 to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-26.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has announced an amendment to the Share Subscription and Shareholders' Agreement to increase its investment in Torrent Urja 27 Private Limited, a wholly-owned subsidiary, to enhance the share of renewable power sources in the company's operations.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has closed its trading window period for Q2, effective from October 1, 2026, and will reopen 48 hours after submitting its financial results for the quarter ended September 30, 2026.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has announced its schedule of investor meets, including Jefferies India forum 2026, Kotak Healthcare Forum 2026, and JP Morgan India Conference, to be held on 17-Sep-26, 18-Sep-26, and 21-Sep-26 respectively.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has announced an investors meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meet will be held on August 14, 2026, at Emkay - Confluence 2026 Mumbai. The company's representatives will participate in group and one-on-one meetings.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has received an ESG rating of 70 from NSE Sustainability Ratings and Analytics Limited.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has completed the dispatch of Postal Ballot Notice to its members through electronic mode, as per the applicable provisions of Companies Act, 2013 and SEBI Listing Regulations.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has announced a postal ballot notice for the appointment of Shanti Ekambaram as an Independent Director of the Company. The e-voting period commences on August 8, 2026, and ends on September 6, 2026.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has released the transcript of its conference call with analysts and investors regarding its financial results for the quarter ended 30th June, 2026. The transcript is available on the company's website.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has informed that Ameera Shah has completed her term as an Independent Director of the Company on 01-Aug-26, and ceased to be the Director of the Company.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has released the audio recording of its conference call with analysts and investors to discuss its Q1 results for the quarter ended 30th June, 2026, which can be accessed on its website.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd announced the change in senior management personnel, with Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni ceasing to be part of the senior management team due to a change in reporting structure, effective July 30, 2026.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd announced its unaudited standalone and consolidated financial results for the quarter ended 30th June, 2026. The Board has approved the financial results along with a limited review report. Ameera Shah will be completing her term as an Independent Director on 01st August, 2026. The financial results will be available on the company's website.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended 30-Jun-26. The Board has approved the results, which will be available on the company's website. Ameera Shah will be completing her term as an Independent Director on 01-Aug-26. The company has also submitted a limited review report by BS R & Co. LLP.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has appointed Shanti Ekambaram as an Additional Independent Director for a term of 3 consecutive years, effective from 30th July, 2026, subject to approval of the shareholders.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd has received final listing and trading approval for 4,19,22,416 equity shares issued and allotted in terms of Scheme of Amalgamation. The shares will be listed and admitted to dealings on NSE and BSE from July 28, 2026.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd announced the declaration of voting results for its 53rd Annual General Meeting held on June 23, 2026. All resolutions proposed were duly approved by shareholders with requisite majority. Key approvals include the adoption of standalone and consolidated financial statements for FY26, confirmation of interim and declaration of final dividend, re-appointment of Samir Mehta as Director, and the crucial approval for the issuance of equity shares including convertible bonds/debentures, which passed with 99.93% votes in favor.
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd held its 53rd Annual General Meeting on June 23, 2026, where shareholders approved the Standalone and Consolidated Financial Statements for the fiscal year ended March 31, 2026. The meeting confirmed an interim dividend of ₹29.00 and declared a final dividend of ₹9.00 per equity share for FY26. Significantly, shareholders also approved the issuance of equity shares, including convertible bonds/debentures, providing the company with flexibility for future fundraising. Additionally, Samir Mehta was re-appointed as Director, and the remuneration of cost auditors for 2026-27 was ratified.